Insights into the use of palbociclib for breast cancer in Sweden
Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)
This study looks at how well palbociclib works for people with metastatic breast cancer in Sweden by gathering information on their treatment experiences and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Sollentuna) |
| Trial ID | NCT04654208 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on patient characteristics, treatment patterns, and clinical outcomes for individuals receiving palbociclib, a medication used in the treatment of metastatic breast cancer, within Swedish clinical practice. By analyzing real-world data, the study seeks to provide insights into how palbociclib is utilized and its effectiveness in a diverse patient population. The study will include patients aged 18 and older who have filled at least one prescription for palbociclib, with no exclusion criteria specified.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been prescribed palbociclib for metastatic breast cancer.
Not a fit: Patients who have not been prescribed palbociclib or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of palbociclib's effectiveness and inform treatment strategies for metastatic breast cancer patients.
How similar studies have performed: Other observational studies have shown success in understanding treatment patterns and outcomes for similar medications in oncology, suggesting this approach is valuable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33) 2. Age ≥18 years at index date Exclusion Criteria: There are no exclusion criteria
Where this trial is running
Sollentuna
- Pfizer Sweden — Sollentuna, Sweden (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.